Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-02
2006-05-02
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S376100
Reexamination Certificate
active
07037931
ABSTRACT:
There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.
REFERENCES:
patent: 4826868 (1989-05-01), Wachter et al.
patent: 5051518 (1991-09-01), Murray et al.
patent: 5164381 (1992-11-01), Wachter et al.
patent: 6750230 (2004-06-01), Corbau et al.
patent: 6750239 (2004-06-01), Hale et al.
patent: 6784185 (2004-08-01), Allerton et al.
patent: 6815428 (2004-11-01), Ohsumi et al.
patent: 6838458 (2005-01-01), Sakya
patent: 6846838 (2005-01-01), Slusarchyk et al.
patent: 6849653 (2005-02-01), Clare et al.
patent: 6852717 (2005-02-01), Cirillo et al.
patent: 6875789 (2005-04-01), Tang et al.
patent: 0 467 614 (1992-01-01), None
patent: 0293220 (1994-08-01), None
patent: WO 95/04720 (1995-02-01), None
patent: WO 97/11704 (1997-04-01), None
patent: WO 01-66539 (2001-09-01), None
patent: WO 01-85723 (2001-11-01), None
patent: WO 01-85724 (2001-11-01), None
patent: WO 01-90078 (2001-11-01), None
Gigoux, V. et al. Arginine 336 and Asparagine 333 of the Human Cholecystokinin-A Receptor Binding Site Interact with the Penultimate Aspartic Acid and the C-terminal Amide of Cholecystokinin. J. Biol. Chem. 1999, 274(29):20457-20464.
Harper, E.A. et al. Analysis of Variation in L-365,260 Competition Curves in Radioligand Binding Assays. Br. J. Pharmacol. 1996, 118:1717-1726.
Hull, R.A. et al. 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)—A Selective Cholecystokinin CCKA-Receptor Antagonist. Br. J. Pharmacol. 1993, 108:734-740.
Klapars, A. et al. A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-Arylation of Nitrogen Heterocycles. J. Am. Chem. Soc. 2001, 123(31):7727-7729.
Klausner, Y.S. and Bodanszky, M. The Azide Method in Peptide Synthesis: Its Scope and Limitations. Synthesis 1974, 8:549-559.
Moradi, W.A. and Buchwald, S.L. Palladium-Catalyzed alpha-Arylation of Esters. J. Am. Chem. Soc. 2001, 123(33):7996-8002.
Morton, M.F. et al. Pharmacological Comparison of the Alternatively Spliced Short and Long CCK2 Receptors. Br. J. Pharmacol. 2003, 140(1):218-224.
Murray, W.V. et al. Synthesis of 3-(1,5-Diphenyl-3-pyrazolyl)aryl Propanates. J. Heterocycl. Chem. 1990, 27:1933-1940.
Penning, T.D. et al. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Indentification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40(9):1347-1365.
Saito, T. et al. Total Synthesis of the Furaquinocins. J. Am. Chem. Soc. 1998, 120(45):11633-11644.
Shen, D.-M. et al. Versatile and Efficient Solid-Phase Syntheses of Pyrazoles and Isoxazoles. Organic Letters 2000, 2(18):2789-2792.
Tullio, P. et al. Therapeutic and Chemical Developments of Cholecystokinin Receptor Ligands. Exp. Opin. Invest. Drugs 2000, 9(1):129-146.
Wang, Z. et al. A New Synthesis for Methyl 2-Benzyloxyphenylacetate. Synth. Commun. 1999, 29(13):2361-2364.
Wolfe, J.P. et al. Simple Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates. J. Org. Chem. 2000, 65(4):1158-1174.
Kirby, Fred B. et al., “Acylation vs. conjugate addition of dipotassio.beta.-diketones with cinnamic esters. Synthesis of unsaturated 1, 3, 5-triketones and tert-butyl 5, 7-dioxoalkanoates”, Abstract—Database CA 'Online! and Journal of Organic Chemistry, vol. 28, No. 9, pp. 2266-2271 (1963).
PCT International Search Report, dated Oct. 23, 2003, for PCT Int'l. Appln. No. PCT/US03/20787.
Barrett Terrance D.
Breitenbucher J. Guy
Gomez Laurent
Hack Michael D.
Huang Liming
Janssen Pharmaceutica N.V.
Lambkin Deborah C.
LandOfFree
CCK-1 receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CCK-1 receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCK-1 receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3600625